Literature DB >> 24048467

Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.

S Apostolakis1, D A Lane, H Buller, G Y H Lip.   

Abstract

Many of the risk factors for stroke in atrial fibrillation (AF) are also important risk factors for bleeding. Wetested the hypothesis that the CHADS2 and CHA2DS2-VASc scores (used for stroke risk assessment) could be used to predict serious bleeding, and that these scores would compare well against the HAS-BLED score, which is a specific risk score designed for bleeding risk assessment. From the AMADEUS trial, we focused on the trial's primary safety outcome for serious bleeding, which was "any clinically relevant bleeding". The predictive value of HAS-BLED/CHADS2/CHA2DS2-VASc were compared by area under the curve (AUC, a measure of the c-index) and the Net Reclassification Improvement (NRI). Of 2,293 patients on VKA, 251 (11%) experienced at least one episode of "any clinically relevant bleeding" during an average 429 days follow up period. Incidence of "any clinically relevant bleeding" rose with increasing HAS-BLED/CHADS2/CHA2DS2-VASc scores, but was statistically significant only for HAS-BLED (p<0.0001). Only HAS-BLED demonstrated significant discriminatory performance for "any clinically relevant bleeding" (AUC 0.60, p<0.0001). There were significant AUC-differences between HAS-BLED (which had the highest AUC) and both CHADS2 (p<0.001) and CHA2DS2VASc (p=0.001). The HAS-BLED score also demonstrated significant NRI for the outcome of "any clinically relevant bleeding" when compared with CHADS2 (p=0.001) and CHA2DS2-VASc (p=0.04). In conclusion, the HAS-BLED score demonstrated significant discriminatory performance for "any clinically relevant bleeding" in anticoagulated patients with AF, whilst the CHADS2 and CHA2DS2-VASc scores did not. Bleeding risk assessment should be made using a specific bleeding risk score such as HAS-BLED, and the stroke risk scores such as CHADS2 or CHA2DS2-VASc scores should not be used.

Entities:  

Keywords:  Atrial fibrillation; CHA2DS2-VASc; CHADS2; HAS-BLED; bleeding risk; oral anticoagulation

Mesh:

Substances:

Year:  2013        PMID: 24048467     DOI: 10.1160/TH13-07-0552

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  24 in total

1.  Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians.

Authors:  Anwar Santoso; Sunu B Raharjo
Journal:  Int J Angiol       Date:  2020-05-06

2.  The changing characteristics of atrial fibrillation patients treated with warfarin.

Authors:  Andrew Putnam; Xiaokui Gu; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Gregory D Krol; Scott Kaatz; James B Froehlich; Geoffrey D Barnes
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

3.  Validation Of The HAS-BLED Tool In Atrial Fibrillation Patients Receiving Rivaroxaban.

Authors:  E W Gorman; D Perkel; D Dennis; J Yates; R E Heidel; D Wortham
Journal:  J Atr Fibrillation       Date:  2016-08-31

Review 4.  Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know.

Authors:  Alpesh Amin
Journal:  Ochsner J       Date:  2016

5.  International Validity of the HOSPITAL Score to Predict 30-Day Potentially Avoidable Hospital Readmissions.

Authors:  Jacques D Donzé; Mark V Williams; Edmondo J Robinson; Eyal Zimlichman; Drahomir Aujesky; Eduard E Vasilevskis; Sunil Kripalani; Joshua P Metlay; Tamara Wallington; Grant S Fletcher; Andrew D Auerbach; Jeffrey L Schnipper
Journal:  JAMA Intern Med       Date:  2016-04       Impact factor: 21.873

Review 6.  Management of Atrial Fibrillation in Patients With Kidney Disease.

Authors:  Yee C Lau; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

Review 7.  Stroke And Bleeding Risk Assessment: Where Are We Now?

Authors:  Mikhail S Dzeshka; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

8.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

Review 9.  Resumption of Anticoagulation After Intracranial Hemorrhage.

Authors:  Ivan Rocha Ferreira da Silva; Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2017-09-30       Impact factor: 3.598

10.  Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.

Authors:  Ethan D Borre; Adam Goode; Giselle Raitz; Bimal Shah; Angela Lowenstern; Ranee Chatterjee; Lauren Sharan; Nancy M Allen LaPointe; Roshini Yapa; J Kelly Davis; Kathryn Lallinger; Robyn Schmidt; Andrzej Kosinski; Sana M Al-Khatib; Gillian D Sanders
Journal:  Thromb Haemost       Date:  2018-10-30       Impact factor: 6.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.